My work is centered on advancing the field of aging biology and translating research into therapies that can extend healthspan. Throughout my work, I’ve contributed to numerous high-impact projects, with a focus on discovering and validating new therapeutic targets, investigating small-molecule interventions, and understanding the underlying mechanisms of cellular quality control. I have published over 30 peer-reviewed articles, including senior-authored works, appearing in top-tier journals such as Nature Aging, Science, Cell Metabolism, Nature Communications, PNAS, Aging Cell, and eLife.I co-founded an early-stage drug discovery startup aimed at addressing aging-related diseases by targeting mitochondrial dysfunction. I also bring experience as an advisor to startups, helping shape their research strategies and guiding their scientific development.My work with the family offices group at Carlyle Global Advisors, along with insights gained from key leaders, has shaped my perspective on strategic investments. This blend of scientific expertise, entrepreneurial experience, and investment perspective positions me to identify and support promising ventures in the longevity space. I am passionate about translating science into real-world solutions and am committed to mentoring the next generation of scientists. If you share similar interests, I’d be delighted to connect on LinkedIn.